MedTrace Logo

Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial

NCT02650336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 592

Last updated 2016-01-08

No results posted yet for this study

Summary

Biomarkers such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) have been used for the early diagnosis of AKI, although with no definitive results. The investigators explored the association between plasma aging biomakers such as sklotho and contrast induced nephropathy in patients undergoing percutaneous coronary intervention (PCI) with contrast injection.

Conditions

  • Contrast Induced Nephropathy

Interventions

DRUG

contrast

a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • zhimin du, MD · fitst affiliated hospital of SYSU

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02650336 on ClinicalTrials.gov